PMID- 11108256
OWN - NLM
STAT- MEDLINE
DCOM- 20001222
LR  - 20231213
IS  - 0013-7227 (Print)
IS  - 0013-7227 (Linking)
VI  - 141
IP  - 12
DP  - 2000 Dec
TI  - Role of endogenous nociceptin in the regulation of arginine vasopressin release 
      in conscious rats.
PG  - 4466-71
AB  - The effects of central administration of the opioid-like peptide nociceptin (also 
      known as orphanin FQ) were investigated on the secretion of arginine vasopressin 
      (AVP) in response to dehydration and hyperosmolar or hypovolemic stimulation in 
      conscious rats. Intracerebroventricular (i.c.v.) administration of nociceptin 
      suppressed plasma AVP concentration in a dose-dependent manner (0.1-10 
      microg/rat) in dehydrated rats, and the maximum effect was obtained 10 min after 
      the administration (dehydration with 10 microg/rat nociceptin, 3.11 +/- 0.27 
      pg/ml vs. control, 10.32 +/- 0.96 pg/ml). The plasma AVP increase in response to 
      either hyperosmolality [i.p. injection of hypertonic saline (HS) (600 mosml/kg)] 
      or hypovolemia [i.p. injection of polyethylene glycol (PEG)] was also 
      significantly blunted when nociceptin was injected i.c.v. (HS with 10 microg/rat 
      nociceptin, 1.16 +/- 0.09 pg/ml vs. control, 1.82 +/- 0.30 pg/ml; PEG with 10 
      microg/rat nociceptin, 0.91 +/- 0.16 pg/ml vs. control, 2.41 +/- 0.26 pg/ml). 
      Pretreatment with a selective opioid kappa-receptor antagonist, 
      nor-binaltorphimine (1 microg/ rat, i.c.v.) or naloxone (2.5 mg/rat, s.c. 
      injection) did not reverse the inhibitory effects of nociceptin on AVP release. 
      Moreover, when plasma AVP was suppressed by acute water loading, 
      immunoneutralization of endogenous nociceptin by antinociceptin-antiserum i.c.v. 
      significantly reversed the suppression (0.57 +/- 0.12 pg/ml vs. control, 0.25 +/- 
      0.04 pg/ml). These results suggest that central nociceptin is physiologically 
      involved in the control of AVP release through an inhibitory action.
FAU - Kakiya, S
AU  - Kakiya S
AD  - First Department of Internal Medicine, Nagoya University School of Medicine, 
      Japan. skakiya@med.nagoya-u.ac.jp
FAU - Murase, T
AU  - Murase T
FAU - Arima, H
AU  - Arima H
FAU - Yokoi, H
AU  - Yokoi H
FAU - Iwasaki, Y
AU  - Iwasaki Y
FAU - Miura, Y
AU  - Miura Y
FAU - Oiso, Y
AU  - Oiso Y
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
RN  - 0 (Antibodies)
RN  - 0 (Opioid Peptides)
RN  - 0 (Receptors, Opioid)
RN  - 0 (Saline Solution, Hypertonic)
RN  - 113-79-1 (Arginine Vasopressin)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
SB  - IM
MH  - Animals
MH  - Antibodies/administration & dosage
MH  - Arginine Vasopressin/*metabolism
MH  - Blood Volume
MH  - Dehydration
MH  - Hypovolemia
MH  - Injections, Intraventricular
MH  - Kinetics
MH  - Male
MH  - Opioid Peptides/administration & dosage/immunology/*physiology
MH  - Polyethylene Glycols/administration & dosage
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Opioid/agonists
MH  - Saline Solution, Hypertonic/administration & dosage
MH  - Nociceptin
EDAT- 2000/12/07 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/12/07 11:00
PHST- 2000/12/07 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/12/07 11:00 [entrez]
AID - 10.1210/endo.141.12.7809 [doi]
PST - ppublish
SO  - Endocrinology. 2000 Dec;141(12):4466-71. doi: 10.1210/endo.141.12.7809.